CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 6 incoming connections
- ScaleMarket cap is $1.61B, above the global median of $1.18B
- PositionGross margin is 88.9%, higher than 95% of its Diagnostics & Research peers (median 56.7%)
- Interpretations10 currently firing — 10
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.13%
Annual Rate
INR 2.00Paid annual
Payout Ratio
11.0%Sustainable
Last Ex-Dividend
Sep 16, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
154.64BINR1.61B · vs all stocks (USD)
Trailing P/E
82.68xvs Diagnostics & Research peers
Revenue (TTM)
8.57BINR89.32M · vs all stocks (USD)
Profit Margin
21.87%vs Diagnostics & Research peers
Beta
0.3570xvs all stocks
52-Week Change
49.00%vs all stocks
Market Capitalization
154.64BINR1.61B · vs all stocks (USD)
Enterprise Value
155.84BINR1.62B · vs all stocks (USD)
Trailing P/E
82.68xvs Diagnostics & Research peers
Forward P/E
54.66xvs Diagnostics & Research peers
PEG Ratio
1.58xPrice to Sales (TTM)
18.04xvs Diagnostics & Research peers
Price to Book (MRQ)
16.13xvs Diagnostics & Research peers
Enterprise to Revenue
18.18xvs Diagnostics & Research peers
Enterprise to EBITDA
42.00xvs Diagnostics & Research peers
Gross Margin
88.92%vs Diagnostics & Research peers
Profit Margin
21.87%vs Diagnostics & Research peers
Operating Margin
31.79%vs Diagnostics & Research peers
Return on Assets (TTM)
11.48%vs Diagnostics & Research peers
Return on Equity (TTM)
18.07%vs Diagnostics & Research peers
Revenue (TTM)
8.57BINR89.32M · vs all stocks (USD)
Revenue per Share (TTM)
83.24INRUpdated Sep 29, 2026Quarterly Revenue Growth
22.80%vs Diagnostics & Research peers
Gross Profit (TTM)
7.58BINR79.02M · vs all stocks (USD)
EBITDA (TTM)
3.77BINR39.26M · vs all stocks (USD)
Net Income (TTM)
1.87BINR19.54M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
38.50%vs Diagnostics & Research peers
Operating Cash Flow (TTM)
2.71BINR28.20M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
1.73BINR18.03M · vs all stocks (USD)
Trailing Annual Dividend Rate
2.00INRUpdated Sep 29, 2026Trailing Annual Dividend Yield
0.13%vs all stocks
Payout Ratio
11.00%vs Diagnostics & Research peers
Revenue
8.14BINRFY2026 · Mar 31, 2026Cost of Goods Sold
946.84MINRFY2026 · Mar 31, 2026Gross Profit
7.20BINRFY2026 · Mar 31, 2026Operating Income
2.45BINR25.54M · vs all stocks (USD)
Pre-tax Income
2.33BINRFY2026 · Mar 31, 2026Income Tax Expense
597.02MINRFY2026 · Mar 31, 2026Net Income
1.73BINRFY2026 · Mar 31, 2026EBIT
2.66BINRFY2026 · Mar 31, 2026EBITDA (Income Statement)
3.58BINRFY2026 · Mar 31, 2026Other Operating Expenses
2.52BINRFY2026 · Mar 31, 2026Non-operating Interest Expense
332.31MINRFY2026 · Mar 31, 2026EPS (Basic)
16.81INRFY2026 · Mar 31, 2026EPS (Diluted)
16.79INRFY2026 · Mar 31, 2026Basic Shares Outstanding
102.90MSharesFY2026 · Mar 31, 2026Diluted Shares Outstanding
102.90MSharesFY2026 · Mar 31, 2026Preferred Stock Dividends
0.00INRFY2026 · Mar 31, 2026Operating Cash Flow
2.34BINRFY2026 · Mar 31, 2026Free Cash Flow
540.52MINRFY2026 · Mar 31, 2026Cash & Cash Equivalents (End of Period)
396.75MINRFY2026 · Mar 31, 2026Starting Profit (CF Statement)
2.33BINRFY2026 · Mar 31, 2026Stock-based Compensation
17.29MINRFY2026 · Mar 31, 2026Other Non-cash Items
256.36MINRFY2026 · Mar 31, 2026Change in Accounts Receivable (CF)
-79.02MINRFY2026 · Mar 31, 2026Change in Other Assets/Liabilities
-182.05MINRFY2026 · Mar 31, 2026Capital Expenditures
-1.80BINRFY2026 · Mar 31, 2026Purchase of Investments
-822.31MINRFY2026 · Mar 31, 2026Sale of Investments
814.60MINRFY2026 · Mar 31, 2026Net Investing Cash Flow
-1.81BINRFY2026 · Mar 31, 2026Common Dividends Paid
-205.44MINRFY2026 · Mar 31, 2026Net Financing Cash Flow
-173.45MINRFY2026 · Mar 31, 2026Shares Outstanding
103.00MSharesUpdated Sep 29, 2026Float Shares
48.93MSharesUpdated Sep 29, 2026% Held by Insiders
53.48%vs all stocks
% Held by Institutions
39.51%vs all stocks
Total Cash (MRQ)
2.89BINR30.13M · vs all stocks (USD)
Total Cash per Share (MRQ)
28.09INRUpdated Sep 29, 2026Total Debt (MRQ)
4.23BINR44.04M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.4415xvs Diagnostics & Research peers
Current Ratio (MRQ)
2.60xvs Diagnostics & Research peers
Book Value per Share (MRQ)
93.06INRUpdated Sep 29, 2026Total Assets
15.07BINR157.05M · vs all stocks (USD)
Total Current Assets
3.22BINRFY2026 · Mar 31, 2026Total Liabilities
5.50BINRFY2026 · Mar 31, 2026Total Non-current Assets
11.85BINRFY2026 · Mar 31, 2026Total Non-current Liabilities
4.26BINRFY2026 · Mar 31, 2026Total Current Liabilities
1.24BINRFY2026 · Mar 31, 2026Cash & Cash Equivalents
396.75MINRFY2026 · Mar 31, 2026Other Short-term Investments
2.49BINRFY2026 · Mar 31, 2026Accounts Receivable
208.60MINRFY2026 · Mar 31, 2026Inventory
48.92MINRFY2026 · Mar 31, 2026Accounts Payable
375.63MINRFY2026 · Mar 31, 2026Short-term Debt
225.57MINRFY2026 · Mar 31, 2026Other Current Liabilities
53.42MINRFY2026 · Mar 31, 2026Long-term Debt
4.00BINRFY2026 · Mar 31, 2026Other Non-current Liabilities
4.66MINRFY2026 · Mar 31, 2026Common Stock (Book)
102.90MINRFY2026 · Mar 31, 2026Total Shareholders' Equity
9.57BINR99.74M · vs all stocks (USD)
52-Week Low
848.00INRUpdated Sep 29, 202652-Week High
1.59KINRUpdated Sep 29, 202652-Week Change
49.00%vs all stocks
Beta
0.3570xvs all stocks
50-Day MA
1.45KINRUpdated Sep 29, 2026200-Day MA
1.19KINRUpdated Sep 29, 2026Avg 10-Day Volume
147.61KSharesUpdated Sep 29, 2026Avg 30-Day Volume
138.74KSharesUpdated Sep 29, 2026Diluted EPS (TTM)
18.16INRUpdated Sep 29, 202610 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Diagnostic
Rising Operating Income With Low Depreciation on a Capital-Heavy Balance Sheet
Operating income rose four years, with small depreciation on a capital-heavy balance sheet.
Reads
Cash Backing With Revenue And Income Streaks
Revenue has risen in each of three years, profit in all three, and it holds more cash than debt.
Reads
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion Levels
Its gross margin and its cash margin are high for its industry, and its operating margin is high outright.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Net Levels
Its gross and net margins are high for its industry, and its operating margin is high outright.
Reads
Multi-Year FCF With Growth And Margin
Three years of positive free cash flow and rising revenue, four of rising equity, and much of its sales turns into cash.
Reads
Three-Year Positive Free Cash Flow With Elevated ADX Asymmetry And 50w SMA Above 200w SMA
Three years of positive free cash flow, with the 50-week average above the 200-week.
Reads
ROE, ROA, And Operating ROA Elevated
It earns more on its equity than its industry does, and on its assets too — not on borrowing alone.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is 88.9%, higher than 95% of its Diagnostics & Research peers (median 56.7%)Significant
Gross margin: 0.89Industry median: 0.57Industry P95: 0.86Peers compared: 30.00
Operating margin is 31.8%, higher than 95% of its Diagnostics & Research peers (median 8.5%)Significant
Operating margin: 0.32Industry median: 0.09Industry P95: 0.29Peers compared: 30.00
Profit margin is 21.9%, higher than 95% of its Diagnostics & Research peers (median 4%)Significant
Profit margin: 0.22Industry median: 0.04Industry P95: 0.21Peers compared: 30.00
Financial Health
High earnings qualityNotable
Earnings Quality Score: 1.28
High structural barrier to entryNotable
Barrier to Entry: 0.51
Supply Chain
Midstream position: 6 outgoing, 6 incoming connectionsNotable
Outgoing: 6.00Incoming: 6.00
High connectivity hub: 12 industry connectionsNotable
Total Connections: 12.00
Scale
Market cap is $1.61B, above the global median of $1.18BNotable
Market cap (USD): 1,611,511,478.343Global Median: 1,180,223,658.953
Companies that share the same coordination system — how they create, deliver, or capture value.
Guangdong Mingyang Electric Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Akr Corporindo Tbk
Tier 1ProductionThroughput-Bound ConversionFlowRule
Garware Hi-Tech Films Ltd.
Tier 1ProductionThroughput-Bound ConversionSenseMakingRule
Zhuzhou Times New Material Technology Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionRuleSenseMaking
Hunan Meihu Intelligent Manufacturing Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionSenseMakingFlow
Tokai Rika Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Zhejiang Dali Technology Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionSenseMakingRule
Kestra Medical Technologies, Ltd.
Tier 1ProductionThroughput-Bound ConversionRule
Dalian Huarui Heavy Industry Group Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionSenseMakingRisk
Yangling Metron New Materials Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionSenseMakingRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Catalyst Pharmaceuticals Inc.
9 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsCash Backing With Revenue And Income StreaksROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsThree-Year Positive Free Cash Flow With Elevated ADX Asymmetry And 50w SMA Above 200w SMAMulti-Year FCF With Growth And Margin
Xiamen Leading Optics Co., Ltd.
8 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsCash Backing With Revenue And Income StreaksROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsMulti-Year FCF With Growth And Margin
DPM Metals Inc.
8 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsRising Operating Income With Low Depreciation on a Capital-Heavy Balance SheetCash Backing With Revenue And Income StreaksMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsThree-Year Positive Free Cash Flow With Elevated ADX Asymmetry And 50w SMA Above 200w SMAMulti-Year FCF With Growth And Margin